NO991906D0 - Sirkulµrpermutert erythropoietin reseptoragonister - Google Patents

Sirkulµrpermutert erythropoietin reseptoragonister

Info

Publication number
NO991906D0
NO991906D0 NO991906A NO991906A NO991906D0 NO 991906 D0 NO991906 D0 NO 991906D0 NO 991906 A NO991906 A NO 991906A NO 991906 A NO991906 A NO 991906A NO 991906 D0 NO991906 D0 NO 991906D0
Authority
NO
Norway
Prior art keywords
permeated
circulated
receptor agonists
erythropoietin receptor
erythropoietin
Prior art date
Application number
NO991906A
Other languages
English (en)
Norwegian (no)
Other versions
NO991906L (no
Inventor
Charles A Mcwherter
Yiqing Feng
Neena Summers
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO991906L publication Critical patent/NO991906L/no
Publication of NO991906D0 publication Critical patent/NO991906D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO991906A 1996-10-25 1999-04-21 Sirkulµrpermutert erythropoietin reseptoragonister NO991906D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3404496P 1996-10-25 1996-10-25
PCT/US1997/018703 WO1998018926A1 (en) 1996-10-25 1997-10-23 Circularly permuted erythropoietin receptor agonists

Publications (2)

Publication Number Publication Date
NO991906L NO991906L (no) 1999-04-21
NO991906D0 true NO991906D0 (no) 1999-04-21

Family

ID=21873960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991906A NO991906D0 (no) 1996-10-25 1999-04-21 Sirkulµrpermutert erythropoietin reseptoragonister

Country Status (13)

Country Link
US (1) US20060172932A1 (enExample)
EP (1) EP0939816A1 (enExample)
JP (1) JP2001503266A (enExample)
KR (1) KR20000052807A (enExample)
CN (1) CN1234073A (enExample)
AU (1) AU721196B2 (enExample)
BR (1) BR9712675A (enExample)
CA (1) CA2268001A1 (enExample)
CZ (1) CZ130199A3 (enExample)
NO (1) NO991906D0 (enExample)
NZ (1) NZ334546A (enExample)
PL (1) PL189756B1 (enExample)
WO (1) WO1998018926A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
AU2005325768A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
EP1966237A2 (en) * 2005-11-24 2008-09-10 Laboratoires Serono SA Erythropoietin polypeptides and uses thereof
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
WO2013184938A2 (en) 2012-06-08 2013-12-12 Alkermes. Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
CN110144010B9 (zh) * 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
AU8735991A (en) * 1990-09-28 1992-04-28 Ortho Pharmaceutical Corporation Hybrid growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Also Published As

Publication number Publication date
US20060172932A1 (en) 2006-08-03
EP0939816A1 (en) 1999-09-08
NZ334546A (en) 2000-12-22
PL332960A1 (en) 1999-10-25
KR20000052807A (ko) 2000-08-25
NO991906L (no) 1999-04-21
BR9712675A (pt) 1999-10-19
CZ130199A3 (cs) 1999-07-14
CA2268001A1 (en) 1998-05-07
AU5081098A (en) 1998-05-22
CN1234073A (zh) 1999-11-03
WO1998018926A1 (en) 1998-05-07
JP2001503266A (ja) 2001-03-13
PL189756B1 (pl) 2005-09-30
AU721196B2 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
NO991906L (no) Sirkulµrpermutert erythropoietin reseptoragonister
ATA78596A (de) Rotationsviskosimeter
EP0984779A4 (en) SOMATOSTATIN AGONISTS
DE69724663D1 (de) Abstandshalter
ATE215369T1 (de) Carbazolanaloge als selektive beta3-adrenergische agonisten
DE69718508D1 (de) Antitraspirant zusammensetzung
DE59711530D1 (de) Färbemittel
ATE222083T1 (de) Fixierende, glanzgebende kosmetische zusammensetzung
ID18359A (id) Komposisi mikrokapsul
DK0810025T3 (da) Homogeniseringsventil
NL1006126A1 (nl) Houder.
ID19589A (id) Komposisi
BR9707835A (pt) Composiç
FI971633A7 (fi) Puristinjärjestelmä
DE69716603D1 (de) Mikroporöse fasern
DK0923562T3 (da) Substituerede p-trifluormethylphenyluraciler
DE59707428D1 (de) Substituierte 1-methyl-3-benzyluracile
BR9709815A (pt) Composicão
DE59711889D1 (de) Substituierte pyrazol-3-ylbenzazole
DE19782032T1 (de) Konzepthalter
DE69707199D1 (de) Dokumentenhalter
DE59712222D1 (de) Substituierte phenyluracile
DE59711493D1 (de) Polymerzusammensetzung
ES1035709Y (es) Bloque para construccion.
FI963935A7 (fi) Polymeerikoostumus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application